ALK and non-small cell lung carcinoma: KEYNOTE 598 [17] compared the efficacy and safety of pembrolizumab combined with or without ipilimumab in the first‐line treatment of EGFR/ALK‐negative and PD‐L1 ≥ 50% Stage IV NSCLC.